Search results - 24 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
hospital study team Source: Eurosurveillance, Volume 28, Issue 47 (2023) Keywords: COVID-19 Omicron Vaccine effectiveness Service: Maladies virales Virale ziekten Viral diseases Épidémiologie des maladies ...
Association between SARS-CoV-2 variants and post COVID-19 condition: findings from a longitudinal cohort study in the Belgian adult population
main exposure variable was the type of SARS-CoV-2 variants (i.e. Alpha, Delta, and Omicron), extracted from national surveillance data. The association between the different SARS-CoV-2 variants and PCC ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
(SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary ...
Genomic monitoring of SARS-CoV-2 variants using sentinel SARI hospital surveillance.
proportions and types were compared to those that were circulating between 2021 and 2022, using 96,251 sequences of the BGS. RESULTS: SARI surveillance allowed timely detection of the Omicron (BA.1, BA.2, BA.4, ...
Time series modelling for wastewater-based epidemiology of COVID-19: A nationwide study in 40 wastewater treatment plants of Belgium, February 2021 to June 2022
of daily flow rate, pepper mild mottle virus (PMM oV) concentration, a measure of human faeces in wastewater, and variants (alpha, delta, and omicron strains) on SARS-CoV-2 RNA levels in wastewater. ...
COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022.
100-150 days after the primary vaccination course. Booster vaccination increased initial VE i to 85% (95% CI: 84-85). Against Omicron, an initial VE i of 33% (95% CI: 30-36) waned to 17% (95% CI: 15-18), ...
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
in 54 patients. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of 6 months after booster vaccination. During this period, SARS-CoV-2 delta and omicron were ...
Homologous versus heterologous prime-boost COVID-19 vaccination: impact on clinical severity of Omicron among hospitalized COVID-19 patients in Belgium
SARS-CoV-2 Omicron infection among hospitalized patients in Belgium, and if this effect is homogenous across different Omicron sub-lineages. Methods Observational data from existing national surveillance ...
Vaccinatiegraad en epidemiologische impact van de COVID-19-vaccinatiecampagne bij personen met onderliggende gezondheidsaandoeningen in België
geschat op 68,2% tegen hospitalisatie en op 73,2% tegen opname op intensieve zorgen, tijdens de Omicron-periode. In vergelijking met personen zonder onderliggende aandoeningen, vertoonden personen met ...
Couverture vaccinale et impact épidémiologique de la campagne de vaccination COVID-19 chez les personnes présentant des maladies sous-jacentes en Belgique
sous-jacentes, la vaccination contre la COVID-19 offre une protection contre une hospitalisation et une admission en USI. Par exemple, au cours de la période de dominance du variant Omicron, la protection initiale ...